Profile: 3M BioApplications is a part of the 3M Inc. focusing mainly on chromatography media.
3M is a world leader in MDI technology and was the first company to successfully use HFA-134a as a propellant. This is one of the important, enabling technologies for the transition of patients from CFC-MDIs which are being phased out under the terms of the Montreal Protocol due to the damaging effects of CFCs on the ozone layer. 3M Pharmaceuticals launched AiromirTM, the world's first CFC-Free MDI in 1995. Airomir, now approved in over 45 countries around the world, contains albuterol, the most popular drug prescribed to relieve the symptoms of an asthma attack. In the United Kingdom, 3M also recently launched QVARTM, an HFA formulation of beclomethasone, an inhaled steroid that helps to reduce the inflammation of asthma in the lungs.<<
There may be more within this diversified company, w/o stretching too much.E.g.